{
}
Wells Fargo has initiated coverage on Kestra Medical Technologies with an Overweight rating and a price target of $28, highlighting the potential of its Assure wearable cardioverter defibrillator. The company is positioned in a $10 billion market, with projected market share growth from 4.8% in 2025 to 15.7% by 2029, driven by advantages in comfort and functionality over competitors. Other analysts, including Stifel and Piper Sandler, have also expressed optimism about Kestra's growth prospects, supported by strategic investments and FDA approvals.
Asahi Kasei Corp
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Wells Fargo sets optimistic price target for Kestra Medical stock
14:38 31.03.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Global Trade Developments
Global Financial Events
Retail and Consumer Goods
Banking Regulations
Central Bank Actions
Startups & Entrepreneurship
Finance Mergers & Acquisitions
Industry Mergers & Acquisitions
Government Economic Policies
Inflation and Monetary Impact
CEO Changes
Market Analysis and Predictions
Domestic Politics
Government Policies
Workplace Trends
GDP Growth & Recession Forecasts
Supply Chain Management
Countries:
Companies:
Tesla, Inc.
Apple Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
The Goldman Sachs Group, Inc.
Credit Suisse Strategic Income I
Banco Santander, S.A.
SpaceXCoin USD
Morgan Stanley
Berkshire Hathaway Inc.
Bank of America Corporation
UBS Group AG
BNP Paribas SA
NVIDIA Corporation
Lloyds Banking Group plc
Bank Frick AG
Citigroup Inc.
Amazon.com, Inc.
Wells Fargo & Company
Currencies:
United States Dollar
Euro
Japanese Yen
British Pound Sterling
Swiss Franc
Indian Rupee
Chinese Yuan
South Korean Won
Canadian Dollar
Vietnamese Đồng
Australian Dollar
Thai Baht
Indonesian Rupiah
Singapore Dollar
Mexican Peso
New Taiwan Dollar
Hong Kong Dollar
Offshore Chinese Yuan
New Zealand Dollar
Cambodian Riel
People: